| |
|
Enabling item level serialization: Ten key steps to ensure success
Item level serialization (ILS) and traceability fosters supply chain integrity. Whether to expose counterfeits, identify sources of product diversion, improve integrity in the reconciliation of returns or comply with increasing regulation, the ability to establish uniqueness at the item level provides unparalleled supply chain accountability and visibility benefits.
|
 |
|
What manufacturers should anticipate when working with specialty pharmacies
When entering the specialty pharmaceuticals arena, manufacturers need to evaluate the capabilities of their channel partners carefully
|
 |
|
Specialty Pharmaceuticals: Facts and Figures
HDMA's fourth edition polling its members and manufacturers, on trends in specialty distribution
|
 |
|
Improving efficiency, effectiveness of drug recalls
Evolving technology and service capabilities are the news in reverse logistics for the pharma industry these days
|
|
2012 Product Security Report
Serialization systems are going into operation around the world, but cross-industry collaboration awaits new legislation
|
|
Home infusion enhances specialty pharmaceutical distribution
With partial support from manufacturers themselves, home health services are emerging as a critical channel for specialties
|
|
Navigating the tense, complex oncology market
Oncology combines some of the most life-changing therapeutic events with the most complex commercialization pathways. Rising costs of treatments simply add to the tension
|
|
Adding rigor to the adverse event reporting process
The widely accepted statistic is that only about 10% of all adverse events (AEs) are reported to FDA. In 2010, that 10% equaled about 750,000 reports, which was an almost 31% increase over 2009 and the biggest year-over-year increase (as a percentage) in the last decade. The estimates for 2011 aren't due for another couple of months (per FDA), but they're expected to continue the upward trend. Pharmacovigilance experts agree that one of the main drivers of recent growth in AE reporting rates is, quite simply, increased awareness . . .
|
|
Generics Manufacturers Grapple With Tight Economics
But the global picture is sunny as most of the global market
growth benefits the generic makers . . .
|
|
THE ONGOING DIABETES BATTLEGROUND
Even as diagnosed (and "prediabetes") cases rise worldwide, healthcare providers struggle with patients to control the course of the disease. New therapies--and new health services--are aiding in the battle . . .
|
|
|
|
|
